Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City

• Published in: Journal of telemedicine and telecare 2023-08, p.1357633X231194796-1357633X231194796
• Main Authors: Chan, Justin, DiTullio, David J, Pagan Pirallo, Patricia, Foote, Mary, Knutsen, Dorothy, Kottkamp, Angelica Cifuentes, McPherson, Tristan D, Mukherjee, Vikramjit, Pitts, Robert, Wallach, Andrew, Wong, Marcia, Mazo, Dana, Mgbako, Ofole
• Format: Article
• Language: English
• ISSN: 1357-633X; 1758-1109
• DOI: 10.1177/1357633X231194796

The 2022 mpox outbreak in New York City posed challenges to rapidly scaling up treatment capacity. We describe a telehealth treatment model launched during this outbreak that facilitated healthcare provider treatment capacity, and was able to adhere to a Centers for Disease Control and Prevention (CDC)-sponsored expanded access investigational new drug (EA-IND) protocol for tecovirimat. Sixty-nine patients were evaluated and prescribed tecovirimat for mpox through telehealth visits at NYC Health + Hospitals/Bellevue and NYU Langone Health from June to August 2022. Thirty-two (46.4%) were previously diagnosed with HIV. Forty-four (63.8%) reported full recovery, with the remainder lost to follow-up. Most patients ( n = 60, 87.0%) attended at least one follow-up visit (either in person or through telehealth) after starting treatment. We observed favorable treatment outcomes, with no serious adverse events, hospitalizations, or deaths related to mpox. While equitable access to telehealth remains a limitation that needs to be addressed, this telehealth model enabled a rapid scale-up of tecovirimat prescription during the mpox outbreak, and should be considered as an important tool used to respond to future infectious disease outbreaks.